

Sun Pharma board to meet on Oct 21: first half results

October 18, 2004, Mumbai: The Board of Directors of the speciality pharma company Sun Pharma will meet on the morning of Thursday October 21st to take on record the unaudited financial results for the quarter and half year ended 30th September, 2004.

A conference call will be held at 4.00 pm the same evening, details of which are as under:

- *India Primary Access: (+91 22) 2781 2322; Secondary Access: (+91 22) 5591 7922*
- *Replay Playback Number: (+91 22) 2788 0506, Standby Number: (+91 22) 5591 7979*

A replay would also be available for three days .The transcript of the call will be put on our website as soon as possible. Dilip Shanghvi (Chairman and Managing Director) and Sudhir Valia (Whole time director) would participate in the call.

Sun Pharma is ranked 5th among all Indian pharma companies with a 3.20%MS (IMS -ORG Retail Store Audit, August 2004). The company continues to lead with a top rank in high growth niche therapy areas such as psychiatry, neurology, cardiology, diabetology, gastroenterology, ophthalmology, orthopedics (CMARC March - June 2004).

Initiatives in research have recently been strengthened, with additional 250,000 sq ft of research floor area across 2 new sites commissioned, 220 scientists being hired, and continuing commitments of \$15 mill to R&D for each of the next two years. Sun Pharma participates in the US generic market though a subsidiary, Caraco Pharm Labs (AMEX CPD), which markets 14ANDAs and had reported a \$45 mill turnover for December 2003. Sun Pharma has also recently begun filing for the US market from an Indian site.

Mira Desai, Corporate Communications

Phone :022-28212128/ 2/8230102/28211961 ext 243

E-mail: corpcomm@sunpharma.com